Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Abbott Laboratories : Sucampo and Abbott Announce Approval for AMITIZA® in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
07/05/2012 | 02:55pm CET

Japan's First Prescription Medicine for Chronic Constipation

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) (SPI) and Abbott (NYSE:ABT) today announced that Sucampo Pharma, Ltd., a wholly owned subsidiary of SPI, has received approval from the Ministry of Health, Labor and Welfare in Japan for AMITIZA® (lubiprostone), a prescription medicine for the treatment of chronic constipation (excluding constipation caused by organic diseases).

"We are very pleased to receive Japan's first-ever approval for a prescription medicine for chronic constipation as it helps us achieve our objective of bringing medicines with novel mechanisms of action to patients with unmet medical needs on a global basis," said Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo's Chairman and Chief Executive Officer. "We look forward to working with Abbott to meet the needs of these patients in Japan."

In 2009, Sucampo and Abbott Japan Co. Ltd. entered into a license, commercialization and supply agreement for AMITIZAin Japan.

About the AMITIZA Development Program in Japan

Sucampo submitted a marketing application to the Japanese Pharmaceuticals and Medical Devices Agency for approval to market AMITIZA in September 2010. The application included data from a Phase 3 efficacy trial in 124 Japanese patients as well as from a long-term open-label safety trial in 209 Japanese patients who received lubiprostone for up to 48 weeks. The application also included data from previous trials conducted in the United States, Canada and Europe.

About Chronic Constipation (excluding constipation caused by organic diseases)

Thousands of people in Japan live daily with the pain and discomfort of chronic constipation, yet many do not seek physician care. Medical attention could mean early diagnosis and effective, long-term treatment.


AMITIZA (lubiprostone) is a prostone, a local activator of type-2 chloride ion channels (ClC-2) in cells lining the small intestine. By increasing intestinal fluid secretion, lubiprostone increases motility in the intestine, thereby facilitating the passage of stool and alleviating symptoms associated with chronic constipation. Additionally, activation of ClC-2 by lubiprostone has been shown to stimulate recovery of mucosal barrier function via the restoration of tight junction protein complexes in ex vivo studies of ischemic porcine intestine.

AMITIZA is approved in the United States for the treatment of two constipation-related indications and in Switzerland for one constipation-related indication.

AMITIZA is a registered trademark of Sucampo Pharmaceuticals, Inc.

About Sucampo Pharmaceuticals

Sucampo Pharmaceuticals, Inc., an international pharmaceutical company, is focused on the discovery, development and commercialization of proprietary drugs based on prostones. The therapeutic potential of prostones, which occur naturally in the human body as a result of enzymatic (15-PGDH) transformation of certain fatty acids, was first identified by Ryuji Ueno, M.D., Ph.D., Ph.D., Sucampo Pharmaceuticals' Chairman and Chief Executive Officer. Dr. Ueno founded Sucampo Pharmaceuticals in 1996 with Sachiko Kuno, Ph.D., founding Chief Executive Officer and currently Advisor, International Business Development, and a member of the Board of Directors. For more information, please visit www.sucampo.com.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs approximately 91,000 people and markets its products in more than 130 countries.

Sucampo Forward-Looking Statements

This press release contains "forward-looking statements" as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and involve risks and uncertainties, which may cause results to differ materially from those set forth in the statements. The forward-looking statements may include statements regarding product development, product potential, future financial and operating results, and other statements that are not historical facts. The following factors, among others, could cause actual results to differ from those set forth in the forward-looking statements: the impact of pharmaceutical industry regulation and health care legislation; Sucampo's ability to accurately predict future market conditions; dependence on the effectiveness of Sucampo's patents and other protections for innovative products; the risk of new and changing regulation and health policies in the US and internationally and the exposure to litigation and/or regulatory actions.

No forward-looking statement can be guaranteed and actual results may differ materially from those projected. Sucampo undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Forward-looking statements in this presentation should be evaluated together with the many uncertainties that affect Sucampo's business, particularly those mentioned in the risk factors and cautionary statements in Sucampo's Form 10-K for the year ended Dec. 31, 2011, which the Company incorporates by reference.

Sucampo Pharmaceuticals, Inc.
Silvia Taylor, 1-240-223-3718
[email protected]
Sucampo Pharmaceuticals, Inc.
Kate de Santis, 1-240-223-3834
[email protected]
Ilke A. Limoncu, +41-61-487-0644
[email protected]

© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
04:06pABBOTT LABORATORIES : Mitraclip therapy receives national reimbursement in japan..
03/21ABBOTT : Hosts Conference Call for First-Quarter Earnings
03/21ABBOTT LABORATORIES : $30,000 Federal Contract Awarded to Abbott Laboratories
03/21ABBOTT LABORATORIES PAKISTAN : Annual general meeting of Abbott Laboratories Lim..
03/19ABBOTT : 's MitraClip Therapy Receives National Reimbursement in Japan to Treat ..
03/16GLOBAL MARKET OVERVIEW FOR MEDICAL M : Research details developments in the Glob..
03/16Drug Makers Use Nanotechnology to Improve Delivery and Dosing
03/15ABBOTT LABORATORIES : Trademark Application for "LUVOX" Filed by Abbott Laborato..
03/15ABBOTT LABORATORIES : An Application for the Trademark "TNI-NX" Has Been Filed b..
03/15ABBOTT LABORATORIES : Patent Application Titled "Nutritional Formulations Includ..
More news
News from SeekingAlpha
03/20FDA Ad Com tomorrow for reclassification of certain laboratory devices used i.. 
03/19ABBOTT LABORATORIES : Nutritionally Unhealthy? 
03/16Key events next week - healthcare 
03/15Cintas Is A Great Operator - Cramer's Lightning Round (3/14/18) 
03/12Abbott HeartMate 3 shows treatment benefit in large-scale study 
Financials ($)
Sales 2018 30 855 M
EBIT 2018 6 454 M
Net income 2018 3 041 M
Debt 2018 13 995 M
Yield 2018 1,78%
P/E ratio 2018 40,61
P/E ratio 2019 33,56
EV / Sales 2018 4,00x
EV / Sales 2019 3,67x
Capitalization 109 B
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Average target price 68,2 $
Spread / Average Target 8,8%
EPS Revisions
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Randel W. Woodgrift VP-Abbott Medical Devices Cardiovascular
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-6.09%351 989
PFIZER0.30%216 268
NOVARTIS-5.95%212 073
ROCHE HOLDING LTD.-11.12%198 243
MERCK AND COMPANY-2.81%147 455